VRX
Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International Inc historical holders
total: 14
Eagle Capital Management Valeant Pharmaceuticals International Inc transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 8
- Held since:
- 2014 Q2
- Held for:
- 13 quarters
- Latest activity:
- 2017 Q3
Eagle Capital Management has been an institutional investor in Valeant Pharmaceuticals International Inc (VRX) since 2014 Q2. According to 2026 Q1 report, Eagle Capital Management doesn't hold any shares. The fund/company first acquired VRX in 2014 Q2, initially purchasing about 3.77M shares. Since the initial investment, Eagle Capital Management has made 11 more transactions in this position.
When did Eagle Capital Management exit their VRX position?
Eagle Capital Management no longer holds Valeant Pharmaceuticals International Inc (VRX). They sold off their entire position in 2017 Q3, closing out an investment that began in 2014 Q2.
When did Eagle Capital Management first invest in VRX?
Eagle Capital Management first invested in Valeant Pharmaceuticals International Inc (VRX) in 2014 Q2 at the reported quarter-end price of $126.12 per share, acquiring 3,769,651 shares in their initial purchase.
What is Eagle Capital Management's average cost basis for VRX?
Based on historical transaction data, Eagle Capital Management's estimated cost basis for Valeant Pharmaceuticals International Inc (VRX) is approximately $114.42 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $114.42
- Weighted AVG sell price:
- $34.90
VRX transactions history by Eagle Capital Management
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2017 Q3
|
0.00%
|
$17.28
|
-100% (-15,918)
|
|||
|
2016 Q4
|
0.00%
|
$14.51
|
-45.40% (-13,235)
|
|||
|
2016 Q3
|
0.00%
|
$24.56
|
-6.72% (-2,100)
|
|||
|
2016 Q2
|
0.00%
|
$20.13
|
-99.47% (-5,867,292)
|
|||
|
2016 Q1
|
0.65%
|
$26.30
|
-16.14% (-1,135,554)
|
|||
|
2015 Q4
|
2.92%
|
$101.65
|
+108.43% (+3,659,378)
|
|||
|
2015 Q3
|
2.64%
|
$178.38
|
-1.37% (-46,855)
|
|||
|
2015 Q2
|
2.99%
|
$222.15
|
-9.52% (-359,951)
|
|||
|
2015 Q1
|
2.79%
|
$198.62
|
-3.39% (-132,555)
|
|||
|
2014 Q4
|
2.11%
|
$143.11
|
-0.29% (-11,392)
|
|||
|
2014 Q3
|
1.99%
|
$131.20
|
+4.13% (+155,823)
|
|||
|
2014 Q2
|
1.88%
|
$126.12
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.